

# Novel Cytomegalovirus Vaccine

Tech ID: 32414 / UC Case 2017-090-0

## TECHNOLOGY DESCRIPTION

Human cytomegalovirus (CMV) infects half of the population of the United States, resulting in lifelong persistent infection. CMV infects 20,000 – 40,000 infants born every year in the United States, resulting in permanent disabilities in twenty percent of those infected. Additionally, CMV infections are a tremendous burden in immunocompromised and transplant patients. Currently, there is no approved vaccine for the treatment of adult or congenital CMV-associated disease. The invention disclosed includes a repertoire of viral peptides (and their sequences) purified from the HLA-E proteins in cells infected with a human CMV strain. These identified peptide sequences could serve as candidates for the development of a CMV vaccine. The novelty of this approach lies in the use of peptides/immunogens presented by the HLA-E major histocompatibility complex I, which has not been used before. This work is currently in the pre-clinical development stage.

## ADVANTAGES

- Identification of novel HLA-E associated viral peptides to serve as potential immunogens for a CMV vaccine.
- HLA-E associated immunogens have been shown to elicit both natural killer cell and T-cell responses, important for innate and adaptive immunity and subsequent host protection.

## PATENT STATUS

Patent Pending

## CONTACT

Gemma E. Rooney  
[Gemma.Rooney@ucsf.edu](mailto:Gemma.Rooney@ucsf.edu)  
 tel: 415-625-9093.



## OTHER INFORMATION

### KEYWORDS

Cytomegalovirus Vaccine,  
 CMV, HLA-E proteins

### CATEGORIZED AS

- ▶ [Medical](#)
- ▶ [Vaccines](#)

### RELATED CASES

2017-090-0

## ADDRESS

**UCSF**

**Innovation Ventures**

600 16th St, Genentech Hall, S-272,  
 San Francisco, CA 94158

## CONTACT

Tel:

[innovation@ucsf.edu](mailto:innovation@ucsf.edu)

<https://innovation.ucsf.edu>

Fax:

## CONNECT

 Follow  Connect

© 2024, The Regents of the University of  
 California

